The targeted therapies for CRC include Bevacizumab (Avastin), which targets VEGF and blood vessel formation, and Cetuximab (Erbitux), which targets epidermal growth factor receptor) [1]. This evidence concerns the gene EGFR and colorectal carcinoma.